These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3149454)

  • 1. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
    Moguilewsky M; Tournemine C
    Am J Clin Oncol; 1988; 11 Suppl 2():S148-51. PubMed ID: 3149454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats.
    Dhar JD; Setty BS
    Contraception; 1990 Jul; 42(1):121-38. PubMed ID: 2387152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
    Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
    Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in testis, epididymis and other accessory organs of male rats treated with anandron during sexual maturation.
    Dhar JD; Setty BS
    Endocr Res; 1990; 16(2):231-9. PubMed ID: 2344837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat.
    Lefebvre FA; Séguin C; Bélanger A; Caron S; Sairam MR; Raynaud JP; Labrie F
    Prostate; 1982; 3(6):569-78. PubMed ID: 6296803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
    Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and clinical studies of the antiandrogen Anandron.
    Moguilewsky M; Bertagna C; Hucher M
    J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
    Labrie F; Dupont A; Bélanger A; Emond J; Monfette G
    Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3861-3. PubMed ID: 6427777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the chronic administration of a potent luteinizing hormone releasing hormone analog on the rat prostate.
    Trachtenberg J
    J Urol; 1982 Nov; 128(5):1097-100. PubMed ID: 6294350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total androgen blockade for metastatic cancer of the prostate.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
    Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
    Labrie F; Dupont A; Belanger A; Lacoursiere Y; Raynaud JP; Husson JM; Gareau J; Fazekas AT; Sandow J; Monfette G
    Prostate; 1983; 4(6):579-94. PubMed ID: 6415630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
    Séguin C; Cusan L; Bélanger A; Kelly PA; Labrie F; Raynaud JP
    Mol Cell Endocrinol; 1981 Jan; 21(1):37-41. PubMed ID: 6259002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].
    Raynaud JP; Coussediere D; Moguilewsky M; Pottier J; Labrie F
    Bull Cancer; 1986; 73(1):36-46. PubMed ID: 3779121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
    Gaillard-Moguilewsky M
    Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.